WaveMan
WaveMan · Company
LFWD · Lifeward Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

LFWD Lifeward (LFWD) Insider Trading, Ownership & Congress Trades

Medical Devices · Orthopedic, prosthetic & surgical appliances & supplies · CIK 0001607962
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
4
13F, latest reported quarter

What the filings say about LFWD

Activist stakes (13D), 180 days
1 filing
Largest: 49.9% of the class

Lifeward insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Lifeward Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Lynch Jeannine
VP of Market Access & Strategy
SELL
2025-09-04 SECtraded 2025-09-02
1,591
$1.0K
-4.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Sep 3, 2024.
  • The trade is 3.5% of the 46,067 shares held after it.
  • No other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP of Market Access & Strategy Lynch Jeannine sold about $1.0K of LFWD on Sep 2, 2025; 4 funds added in the latest 13F quarter.
Jasinski Lawrence J
Chief Executive Officer
SELL
2025-05-22 SECtraded 2025-05-21
1,909
$2.4K
-59.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 13, 2024.
  • The trade is 1.9% of the 98,728 shares held after it.
  • No other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Jasinski Lawrence J sold about $2.4K of LFWD on May 21, 2025; 4 funds added in the latest 13F quarter.
Richner Randel
Director
SELL
2024-12-17 SECtraded 2024-12-13
4,285
$7.2K
-66.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • No other insider sold within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Richner Randel sold about $7.2K of LFWD on Dec 13, 2024; 4 funds added in the latest 13F quarter.
Turk Joseph E Jr
Director
BUY
2024-12-17 SECtraded 2024-12-13
6,000
$10.1K
-66.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 23, 2024.
  • -26.3% median (-26.3% mean) 90-day return after 2 previous buys.
  • The trade is 32.4% of the 18,516 shares held after it.
  • 1 other insider bought within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Turk Joseph E Jr bought about $10.1K of LFWD on Dec 13, 2024; 1 other insider bought within 30 days and 4 funds added in the latest 13F quarter.
Swinford Michael
Director
BUY
2024-11-27 SECtraded 2024-11-25
21,622
$43.9K
-75.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 22, 2024.
  • +2.2% median (+2.2% mean) 90-day return after 2 previous buys.
  • The trade is 33.2% of the 65,040 shares held after it.
  • 1 other insider bought within 30 days.
  • 4 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Swinford Michael bought about $43.9K of LFWD on Nov 25, 2024, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 4 funds added in the latest 13F quarter.
17 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 12 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
4 funds bought in last quarter
below 98% of Medical Devices
Revenue
-94.5% year over year
below 98% of Medical Devices
Margin
-1422.4% net margin
below 99% of Medical Devices
Buybacks
no share repurchases reported
Short interest
6.2% of the float short (float per yahoo 2026-10-26) · 22.7 days to cover · settled 2026-09-30
below 51% of Medical Devices
The situation: each line is one rule over one dataset
Oramed Pharmaceuticals Inc. disclosed a 5%+ stake (49.9%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LFWD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-22.1%12M
-41%-22%-2%+17%2025-102025-122026-022026-042026-062026-082026-10 2026-05-14 · Oramed Pharmaceuticals Inc. filed a 5%+ stake (49.9%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LFWD: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
18,064 sh
$141.8K
RENAISSANCE TECHNOLOGIES LLC
11,327 sh
$86.8K
UBS Group AG
2,152 sh
$16.5K
MORGAN STANLEY
274 sh
$2.1K
SBI Securities Co., Ltd.
196 sh
$1.5K

Congress trades in LFWD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Oramed Pharmaceuticals Inc.
Activist 13D · 2026-05-14
49.9%

LFWD planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LFWD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Dimensional US Core Equity 1 ETF
$5.7K position · as of 2026-07-31
0.0%
Dimensional U.S. Core Equity 2 ETF
$690 position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Larry Jasinski
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$854.0K
$642.6K
$471.1K
-38%
n/a
2021
$927.5K
$848.0K
$431.3K
-7%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 4 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

LFWD financials

Revenue growth
-94.5%
XBRL, annual
Net margin
-1422.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-141.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$17.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.28x
long-term 2020-09-30 (69 months older than the period end) plus current 2020-09-30 (69 months older than the period end); equity 2026-06-30
Cash flow to debt
-4.97x
TTM operating cash flow over long-term 2020-09-30 (69 months older than the period end) plus current 2020-09-30 (69 months older than the period end)
Return on equity
-225.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-99.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-113.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$11.1M
market value at close 2026-10-23 on 2026-08-12 shares, plus long-term 2020-09-30 (69 months older than the period end) plus current 2020-09-30 (69 months older than the period end), minus cash 2026-06-30
FCF yield
-99.6%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$22.0M$25.7M$13.9M$5.5M
Gross profit$8.4M$8.2M$4.5M$1.9M
Operating income-$19.7M-$29.3M-$23.6M-$19.1M
Net income-$19.9M-$28.9M-$22.1M-$19.6M
EPS (diluted)-17.16-39.96-31.13-2.20
Operating cash flow-$16.8M-$21.7M-$20.7M-$17.9M
Cash$2.2M$6.7M$28.1M$67.9M
SEC XBRL, fiscal years, as known on 2026-10-27

LFWD Stock Sonar score 5/7 axes

Find similar shapesCompare

LFWD ranks highest on financial health (35th percentile) and risk and compliance (34th), and lowest on institutional and government (2nd), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
16
Inputs
  • Return on equity-225.5% · 13 pct, sector of 183
  • Return on assets-99.8% · 18 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-113.0% · 16 pct, sector of 188
Financial health
35
Inputs
  • Debt to equity0.28x · 51 pct, sector of 159
  • Cash flow to debt-4.97x · 18 pct, sector of 150
Growth
2
Inputs
  • Revenue growth, YoY-94.5% · 2 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
2
Inputs
  • Funds adding, latest quarter4 · 2 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
  • Short interest, % of float+6.2% · 41 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+15.9% · 27 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LFWD filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 49.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies